Science and Technology
December 2, 2014

NEWS & PUBS

arrow

Press Releases

Continue Reading
March 31, 2015

X-Chem and Navitor Pharmaceuticals Enter into License Agreement on Novel Small Molecules Targeting mTORC1 Activation

WALTHAM & CAMBRIDGE, Mass. – March 30, 2015 –X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced that Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, exercised its option to obtain an exclusive […]

Continue Reading
January 9, 2015

X-Chem Announces Collaboration with Janssen and Johnson & Johnson Innovation to Advance Novel Candidates to Treat Inflammatory Diseases

WALTHAM, Mass. – January 9, 2015 – X-Chem, Inc. (“X-Chem”), a privately held biotechnology company applying its cutting-edge drug discovery platform to the generation of novel small molecule therapeutics, today announced a multi-target collaboration with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration, which is being facilitated […]

Continue Reading
January 9, 2015

X-Chem Promotes Diala Ezzeddine to Executive Vice President and Chief Business Officer

WALTHAM, Mass. – January 9, 2015 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced that Diala Ezzeddine, Ph.D., has been promoted to executive vice president and chief business officer, effective December 6, 2014.

Continue Reading
December 17, 2014

X-Chem Licenses Cardiovascular Drug Discovery Program to Bayer Pharma AG

WALTHAM, Mass. – December 17, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has licensed a second drug discovery program to Bayer Pharma AG pursuant to the multi-target collaboration the companies established in July 2012.

Continue Reading
December 10, 2014

X-Chem and Alexion Collaborate to Discover Novel Therapeutic Candidates to Treat Patients with Severe and Ultra-Rare Disorders

WALTHAM, MA – December 11th, 2014 – X-Chem, Inc., a biotechnology company focused on the generation of novel small molecule therapeutics using its proprietary DNA-encoded library platform, today announced the initiation of a drug discovery collaboration with Alexion (Nasdaq: ALXN), a global leader in the development and commercialization of life-transforming therapies for patients with severe […]

Continue Reading
Continue Reading
June 10, 2014

X-Chem Enters into Multi-Target Collaboration with Pfizer Inc.

WALTHAM, Mass. – June 11, 2014 – X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, today announced a multi-target collaboration with Pfizer Inc. The collaboration is focused on the potential development of several programs for the treatment of inflammatory and orphan diseases.

Continue Reading
February 13, 2014

X-Chem Licenses Epigenetic Drug Discovery Program to Bayer Pharma AG

WALTHAM, Mass. – February 13, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has achieved a success milestone with Bayer Pharma AG in the multi-target collaboration the companies established in July 2012.

Continue Reading
February 2, 2014

X-Chem First Biotech to Exceed 100 Billion Compounds with its Unique and Proprietary Small Molecule DNA-Encoded Library

WALTHAM, MA, USA – February 4, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its powerful product engine to the generation of novel small molecule therapeutics, today announced that the company has created the first biotech-owned screening library of DNA-encoded small molecules to ever surpass 100 billion compounds.

Continue Reading